Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 26;12(9):1032–1049. doi: 10.4252/wjsc.v12.i9.1032

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.

PMC Copyright notice

Inhibitory effects of mesenchymal stem cells therapy on graft-versus-host disease severity. A-C: NOG mice were administered 200 cGy of total body irradiation before transplantation of human peripheral blood mononuclear cells (2 × 10⁷). At days 0, 7 and 14 after transplantation, mice were administered with umbilical cord-derived mesenchymal stem cells or bone marrow-derived mesenchymal stem cells (1 × 10⁵). All NOG mice were monitored for survival (A), clinical signs of graft-versus-host disease (B) and weight (C). BM-MSC: Bone marrow-derived mesenchymal stem cells; GVHD: Graft-versus-host disease; UC-MSC: Umbilical cord-derived mesenchymal stem cells.